Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de PIT565 en neoplasias malignas de células B en recaída y/o refractarias

18 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

Un estudio multicéntrico, abierto y de fase I de PIT565 en pacientes con neoplasias malignas de células B en recaída o refractarias

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.

The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).

During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.

Different schedules and routes of administrations will be explored in the dose escalation groups.

The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.

Tipo de estudio

Intervencionista

Inscripción (Actual)

61

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Ghent, Bélgica, 9000
        • Novartis Investigative Site
      • Barcelona, España, 08035
        • Novartis Investigative Site
      • Barcelona, España, 08036
        • Novartis Investigative Site
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • University Of Miami
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Medical Center
    • Kansas
      • Fairway, Kansas, Estados Unidos, 66205
        • The University of Kansas Clinical Research Ctr
    • New York
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Ctr
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health Sciences University
      • Créteil, Francia, 94010
        • Novartis Investigative Site
      • Marseille, Francia, 13273
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Novartis Investigative Site
    • RE
      • Reggio Emilia, RE, Italia, 42123
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japón, 2778577
        • Novartis Investigative Site
      • Beijing, Porcelana, 100730
        • Novartis Investigative Site
      • Shanghai, Porcelana, 200032
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300020
        • Novartis Investigative Site
      • Singapore, Singapur, 119074
        • Novartis Investigative Site
      • Singapore, Singapur, 169608
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Male or female patients ≥18 years of age at the date of signing the informed consent form
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2

NHL patient population

  • Refractory or relapsed B-NHL
  • Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
  • Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan

ALL patient population

  • Refractory or relapsed CD19-positive B-ALL
  • Morphologic disease in the bone marrow (≥ 5% blasts)

Exclusion Criteria:

  • History of severe hypersensitivity to any ingredient of the study treatment or its excipients
  • Contraindication to tocilizumab
  • History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
  • Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
  • Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
  • Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
  • Patients receiving systemic treatment with any immunosuppressive medication

Other protocol-defined inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: PIT565 Group A (dose escalation part)

PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group B (dose escalation part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group A1 (dose expansion part)

PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group A2 (dose expansion part)

PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Experimental: PIT565 Group B1 (dose expansion part)

PIT565 in adult R/R ALL patients.

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence and severity of Dose Limiting Toxicities (DLTs)
Periodo de tiempo: 28 days or 35 days, depending on the dosing schedule

Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol.

28 days or 35 days, depending on the dosing schedule
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: 21 months

Assessment of safety of study drug.

21 months
Frequency of dose interruptions
Periodo de tiempo: 21 months

Assessment of tolerability of study drug

21 months
Frequency of dose reductions
Periodo de tiempo: 21 months

Assessment of tolerability of study drug

21 months
Dose intensities
Periodo de tiempo: 21 months

Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure.

21 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate (ORR)
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Complete Response (CR) rate
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Best Overall Response (BOR)
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Duration Of Response (DOR)
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Overall Survival (OS)
Periodo de tiempo: 33 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

33 months
Progression Free Survival (PFS)
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Event-free survival (EFS)
Periodo de tiempo: 21 months

Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints.

21 months
Maximum concentration of PIT565 (Cmax)
Periodo de tiempo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Area Under the Curve of PIT565 (AUC)
Periodo de tiempo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Trough concentration of PIT565 (C trough)
Periodo de tiempo: 21 months

Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s)

21 months
Prevalence of Anti-drug antibodies (ADA) at baseline
Periodo de tiempo: Baseline

Assessment of anti-PIT565 antibodies in serum.

Baseline
Incidence of Anti-drug antibodies (ADA) on treatment
Periodo de tiempo: 21 months

Assessment of anti-PIT565 antibodies in serum.

21 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de octubre de 2022

Finalización primaria (Estimado)

31 de mayo de 2027

Finalización del estudio (Estimado)

31 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

25 de mayo de 2022

Primero enviado que cumplió con los criterios de control de calidad

25 de mayo de 2022

Publicado por primera vez (Actual)

31 de mayo de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CPIT565A12101
  • 2022-000367-45 (Número EudraCT)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .